In breast cancer, triple negative (TN) breast cancer has most responses to immune checkpoint inhibitor (ICI) therapy. Lymphocyte infiltrate does not impact prognosis in Hormone receptor positive HER2 negative (HR + HER2-) breast tumors and few HR + HER2- tumors respond to ICI. We contrasted immune-associated gene expression between 119 TN and 475 HR + HER2- breast tumors from The Cancer Genome Atlas (TCGA) and confirmed our findings in 299 TN and 1369 HR + HER2- breast tumors in the METABRIC database. TN and HR+ HER2- tumors grouped into immune-high or -low tumors, both subtypes were represented in the immune-high group. The largest difference between the immune-high TN and HR + HER2- tumors was TN tumors had more abundant T and T CD4 T cells while HR + HER2- tumors had more abundant fibroblasts (logFC > 0.3; < 10×10). This suggests an immune-high signature is not dictated by breast cancer subtype, but fibroblast subsets associated with worse outcome were higher in the immune-high HR + HER2- tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326399 | PMC |
| http://dx.doi.org/10.21203/rs.3.rs-4542494/v1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bone-Induced Her2 Promotes Secondary Metastasis in HR+/Her2- Breast Cancer.
Cancer Discov
January 2025
Icahn School of Medicine at Mount Sinai, New York, United States.
Bone metastases can disseminate to secondary sites and promote breast cancer progression creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of Her2-expressing (Her2E) circulating tumor cells (CTCs) after analyzing over 13,000 CTCs from a cohort of 137 metastatic breast cancer (MBC) patients with initial HR+/Her2- status and employ preclinical models of bone metastasis (BM) to validate the role of Her2E CTCs in multi-organ metastases.
View Article and Find Full Text PDFCarcinoma of Unknown Primary: Integrating Timely Interventions and Molecular Advancements for Improved Outcomes.
Cureus
December 2024
Hematology and Medical Oncology, University of Kentucky College of Medicine, Lexington, USA.
Carcinoma of unknown primary (CUP) is a diverse group of malignancies characterized by metastatic disease without an identified primary site. It typically presents with a poor prognosis due to widespread metastasis at diagnosis. This report discusses a 58-year-old female patient with advanced CUP and diffuse liver metastasis.
View Article and Find Full Text PDFExploring utilities of [64Cu]Cu-DOTA-trastuzumab immunoPET in breast cancer: a systematic review and meta-analysis.
Nucl Med Commun
January 2025
Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman, Jordan.
[64Cu]Cu-DOTA-trastuzumab represents a novel immunopositron emission tomography (immunoPET) agent with emerging diagnostic applications in human epidermal growth factor receptor-2 (HER2)-expressing breast cancer (BC). This systematic review and meta-analysis evaluates the current diagnostic utilities of [64Cu]Cu-DOTA-trastuzumab PET/computed tomography (CT) and explores tumor uptake metrics in HER2-positive BC lesions. A systematic literature search of PubMed, Scopus, and Ovid databases was conducted using relevant keywords to identify eligible studies.
View Article and Find Full Text PDFCD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
J Exp Clin Cancer Res
January 2025
Microenvironment and Biomarkers of Solid Tumors Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy.
Background: Growing evidence shows that the reprogramming of fatty acid (FA) metabolism plays a key role in HER2-positive (HER2 +) breast cancer (BC) aggressiveness, therapy resistance and cancer stemness. In particular, HER2 + BC has been defined as a "lipogenic disease" due to the functional and bi-directional crosstalk occurring between HER2-mediated oncogenic signaling and FA biosynthesis via FA synthase activity. In this context, the functional role exerted by the reprogramming of CD36-mediated FA uptake in HER2 + BC poor prognosis and therapy resistance remains unclear.
View Article and Find Full Text PDFLooking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?
Reprod Biol Endocrinol
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Breast cancer (BrCa) is a complex and heterogeneous disease with diverse molecular subtypes, leading to varied clinical outcomes and posing significant treatment challenges. The increasing global burden of BrCa, particularly in low- and middle-income countries, underscores the urgent need for more effective therapeutic strategies. The androgen receptor (AR), expressed in a substantial proportion of breast cancer cases, has emerged as a potential biomarker and therapeutic target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!